Harpoon Therapeutics
Harpoon built small T-cell engager proteins that link a patient's T cells to tumour cells, including HPN328, which targets DLL3 on small cell lung cancer and neuroendocrine tumours. Merck bought the company in early 2024 for about $680 million.
Overview
Harpoon Therapeutics was a South San Francisco clinical-stage company that developed T-cell engagers on its Tri-specific T cell Activating Construct (TriTAC) platform and the ProTriTAC prodrug platform, which keeps the engager inactive until it reaches the tumour. Lead candidate HPN328 is a DLL3-targeting T-cell engager evaluated in patients with small cell lung cancer and neuroendocrine tumours. On 8 January 2024 Merck agreed to acquire Harpoon for $23.00 per share in cash, an approximate total equity value of $680 million, and the merger completed on 11 March 2024, after which Harpoon's Nasdaq listing (HARP) ended. Merck said it would evaluate HPN328 in combinations with its pipeline. The harpoontx.com domain now redirects to merck.com.
Funding
All startupsInvestors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · $23.00 per share in cash, approximate total equity value $680 million; announced 8 January 2024, completed 11 March 2024 | 2024 | $680M | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Notes
top- Former Nasdaq ticker HARP.
Pages like this
not linked directly; found by shared links- CompanyXencor
Shares CD3, T-cell engagers (bispecific).
- TrialTOWER
Shares CD3, T-cell engagers (bispecific).
- CompanyIDEAYA Biosciences
Shares DLL3, Small-cell lung cancer.
- PairingSequencing DLL3 engager and B7-H3 ADC in relapsed SCLC
Shares DLL3, Small-cell lung cancer.
- TrialDeLLphi-305
Shares DLL3, Small-cell lung cancer.
- CompanyJanux Therapeutics
Shares CD3, T-cell engagers (bispecific).
- IdeaSubtype-directed therapy for SCLC (ASCL1 / NEUROD1 / POU2F3 / inflamed)
Shares DLL3, Small-cell lung cancer.
- TermNeuroendocrine tumour grade (Ki-67) and WHO classification